Pharmaceutical Executive, January 2017 Issue (PDF)

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Research has shown a gap between the female patient experience compared to those of men.

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.

View the Pharmaceutical Executive May 2025 issue in an interactive format.

Tapping into the reader experience, our new comprehensive survey uncovers valuable input for navigating the changing tides facing pharma decision-makers.